PROTHENA CORP PLC
PRTANASDAQTrading Snapshot
- Day Range
- $8.73 – $8.94
- 52-Week Range
- $7.73 – $11.80
- Volume
- $3.18B
- Avg Volume
- $2.51B
- Shares Outstanding
- 52.4M
- Next Earnings
- Dec 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 7.8x
- EPS (TTM)
- $-0.83
- Dividend Yield
- —
- Dilution (1yr)
- +0.0%
Why Investors Own PRTA
- ✓High-growth profile — revenue up +54.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 49% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PROTHENA CORP PLC
PRTA
StockOtter · stockotter.spaceAbout PROTHENA CORP PLC
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Prothena Corporation plc (NASDAQ:PRTA) Receives $24.57 Consensus PT from Analysts
Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the firm, MarketBeat.com reports. One e
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference.
KMDA or PRTA: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $1.86 per share a year ago.